Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q2 2018 · 10-Q
Revenue$4.33M$4.33M+54.6% vs Q2 2017 Net Income-$2.87M-$2.87MN/M vs Q2 2017 EPS, diluted—
Gross Profit$1,848,000+78.4% Operating Income-$2,857,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,599,000N/M Free Cash Flowderived-$2,604,000N/M Margins · derivedGross margin42.7%+5.7 pt vs Q2 2017
Operating margin-66.1%+40.7 pt vs Q2 2017
Net margin-66.4%+3.3 pt vs Q2 2017
ended Sep 30, 2017 · filed Nov 14, 2017 · 45 d after period end